Boryung Pharmaceutical, PharmaMar`s partner in South Korea, announces superior potent results for plitidepsin (Aplidin®) against SARS-CoV-2
(WorldNews Belgium)

Boryung Pharmaceutical, PharmaMar`s partner in South Korea, announces superior potent results for plitidepsin (Aplidin®) against SARS-CoV-2  Plitidepsin has showed 2,400~2,800 times higher anti-viral activity than remdesivir.  Boryung Pharmaceutical to begin a clinical trial of plitidepsin in Korea in Q3 2020.  In 2016, PharmaMar and Boryung Pharmaceutical signed a licensing agreement to commercialize plitidepsin in South Korea. Madrid, July 2nd, 2020.- PharmaMar (MSE:PHM) has announced today that its partner in South Korea, Boryung Pharmaceutical, has presented the results of in vitro studies of plitidepsin (Aplidin®) in SARS-CoV-2. According to the repeated evaluation of anti-viral...